Skip to main content
profile image
Selected Works of Heather Brooks, MD
Article
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial
Blood (2014)
  • Jeff P. Sharman, Willamette University
  • Charles M. Farber, Morristown Medical Center
  • Daruka Mahadevan, University of Tennessee Health Science Center
  • Marshall T. Schreeder, Clearview Cancer Institute, Huntsville, AL
  • Heather D. Brooks, Blue Ridge Cancer Care, Blacksburg, VA
  • Kathryn S. Kolibaba, Compass Oncology, Vancouver, WA
  • Suzanne R. Fanning, Greenville Heath System Cancer Institute, Greenville, SC
  • Leonard M. Klein, US Oncology Research, The Woodlands, TX
  • Peter Sportelli, TG Therapeutics, Inc., New York, NY
  • Hari P. Miskin, TG Therapeutics, Inc., New York, NY
  • Michael S. Weiss, TG Therapeutics, Inc., New York, NY
  • Daniel R. Greenwald, Cancer Center of Santa Barbara, Santa Barbara, CA
Link
Disciplines
Publication Date
December 6, 2014
DOI
10.1182/BLOOD.V124.21.4679.4679
Citation Information
Jeff P. Sharman, Charles M. Farber, Daruka Mahadevan, Marshall T. Schreeder, et al.. "Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial" Blood Vol. 124 Iss. 21 (2014) p. 4679 - 4679
Available at: http://works.bepress.com/heather-brooks2/4/